Creatine

Creatine Monohydrate

Evidence & Status

  • Strong Human Evidence
  • Established

At a Glance

Creatine monohydrate has exercise-context evidence and a separate narrow older-adult cognition study; it is not established as a longevity intervention.

Plain English

This entry is only about creatine monohydrate. Exercise research and one older-adult cognition study cannot answer every question about different products, long-term use, disease, or longevity.

Overview

This record is scoped to creatine monohydrate (molecular weight approximately 149.15 g/mol), not anhydrous creatine (approximately 131.13 g/mol) or every creatine-containing product. The cited exercise position stand supports evidence in exercise and training contexts; the selected older-adult trial is a narrow cognition study and does not establish a general cognitive, neuroprotective, sarcopenia, or longevity benefit.

Research Summary

The selected position stand synthesizes creatine supplementation evidence in exercise and training contexts. McMorris et al. studied cognitive performance in elderly participants under its own protocol and endpoints. These sources do not establish disease prevention, neuroprotection, sarcopenia prevention, or longevity benefit.

Research Areas

  • Muscle strength & power
  • Exercise and training research
  • Older-adult cognition study

Safety & Risks

Serious Risks

  • The selected sources do not establish long-term safety for every population, dose, formulation, or coexisting medical condition.
  • Creatine monohydrate study findings should not be generalized to other creatine forms or products.
United States
This record does not establish a U.S. drug approval or therapeutic indication for creatine monohydrate.
United Kingdom
Not assessed in this record.
Australia
Not assessed in this record.
Canada
Not assessed in this record.